Braeburn develops next generation therapies for opioid use disorder and for chronic pain with individualized dosing regimens and delivery options.


Our Programs

Opioid Use Disorder: Braeburn’s New Drug Application (NDA) for BRIXADI™ (CAM2038), our extended-release buprenorphine medication developed for subcutaneous weekly and monthly dosing, has received Tentative Approval from FDA. Learn more about BRIXADI’s clinical trial results and Tentative Approval here.

Chronic Pain: Braeburn is also investigating CAM2038 in opioid tolerant patients with chronic pain as part of its ongoing pivotal Phase III program. Learn more about CAM2038’s clinical trial results here.


Watch the video above for a description of FluidCrystal® Injection Depot Technology. FluidCrystal® Injection Depot Technology is developed by Camurus.

Define the future at Braeburn...together.

Join Our Team